Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly

Completed · Phase 2 · Has a placebo group

Conditions studied: Aging

In brief

The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug to prevent transplant rejection, increases the lifespan and healthspan of mice and ameliorates age-related declines in immune responsiveness, cancer survival, and cognition in laboratory animals. Investigators are conducting a translational trial to test whether rapamycin also improves life functions in humans focusing on elderly persons (aged 70-95).

Key facts

Study ID

NCT02874924

Run by

The University of Texas Health Science Center at San Antonio

People needed

34

Starts

2016-06-01

Expected to finish

2018-09-01

Last updated by the study team

2018-12-04

Who can join

Age: 70 and older, up to 95. Sex: any. Healthy volunteers: accepted.

You may not qualify if…

• unstable ischemic heart disease
• clinically significant pulmonary disease
• history of immunodeficiency or receiving immunosuppressive therapy
• history of a coagulopathy or receiving a medical condition requiring anticoagulation
• an estimated glomerular filtration rate of <30ml/min
• uncontrolled hypercholesteremia >350mg/dl;
• uncontrolled hypertriglyceridemia >500mg/dl
• diabetes
• history of skin ulcers or poor wound healing
• smoking
• liver disease
• treatment with drugs known to affect cytochrome P450 3A (diltiazem, erythromycin)

Where it is running

• UTHSCSA — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.